Biogen's Tecfidera gets NICE's final nod; Novo Nordisk buys biotech plant in NH;

@FiercePharma: Top-read in FP yesterday: Galena says goodbye to ex-CEO, no severance pay included. Article | Follow @FiercePharma

@EricPFierce: Have you seen Armenian Nuritsa Grigoryan, the FDA wants know? She fled just ahead of prison. More | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: China's Luye Pharma founder soars into pharma's billionaire echelon. Story | Follow @CarlyHFierce

> The U.K.'s cost-effectiveness watchdogs gave their final blessing to Biogen Idec's ($BIIB) multiple sclerosis pill Tecfidera. Report

> Novo Nordisk ($NVO) snapped up a production facility in New Hampshire from Olympus Biotech, planning to turn out active pharmaceutical ingredients there. Report

> GlaxoSmithKline ($GSK) nabbed a new indication in the U.S. for Promacta, its blood disorder drug, for patients with a rare bone marrow problem. Report

> The National Institutes of Health released its latest "priority" list of drugs it wants drugmakers to study in children. Report

> Merck Serono has broken ground on its new pharma manufacturing facility in China, which will be the company's second-largest plant on the globe. Release

> South Africa's health department is rewriting rules for drug marketing, aiming to close loopholes that allow "perverse incentives" to influence prescribing. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Researchers develop implant/app combo to monitor glaucoma in aging eyes. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Sci gets bad news on four of 23,000+ vaginal mesh lawsuits. Article | Follow @VarunSaxena2

@EmilyWFierce: Hot on the M&A trail, Medtronic acquires NGC Medical to expand its hospital-services offerings. More from the WSJ | Follow @EmilyWFierce

> Study finds robotic prostate removal surgery results in faster recovery times. Article

> Xprize seeks Star Trek's tricorder in $10M mobile diagnostics competition. More

> Mobile medical app provider reels in $25M to expand innovative monitoring system. Story

Biotech News

@FierceBiotech: What's the #1 biotech hub for VCs? (It's still not Boston). Report | Follow @FierceBiotech

@JohnCFierce: So now we have multiple stories that Novo isn't interested in big deals. It's not a surprise. More from the WSJ | Follow @JohnCFierce

@EmilyMFierce: Thymus gland grown from reprogrammed cells in lab. FierceBiotech Research story | Follow @EmilyMFierce

> Thinking 'big,' Arch Venture gathers a $400M-plus fund to back a new wave of biotechs. Story

> Parkinson's player Civitas Therapeutics files for an $86M IPO. More

> After a string of gene therapy licensing deals, ReGenX says it's time to shine. Article

Drug Delivery News

> Fresenius Kabi receives FDA approval of three-chamber bag for parenteral nutrition. Article

> Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. Story

> Vascular device drug delivery company surpasses VC goal. More

> Louisiana Tech researchers use 3-D printing to create bioresorbable drug delivery system. Report

> PharmaJet secures FDA approval for jet injection system for flu vaccine. Article

Diagnostics News

> Flagship Biosciences and Sarepta will automate muscular dystrophy biomarker detection. Story

> FDA signs off on highly specific Type 1 diabetes biomarker test. Report

> Roche's Ventana expands infrastructure in Arizona. More

> UCLA, Harvard and others identify possible TB biomarker. Story

> Illumina, AstraZeneca, Janssen and Sanofi to pursue universal companion Dx test. Article

Pharma Marketing News

> Who's doing the mobile app dance right? Only a few in pharma, report says. Story

> Big Pharma, Big Biotech prepare for showdown in next-gen psoriasis market. Report

> Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C. News

> PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready. Article

> Listen to celebrity drug ads? Patients do hear, but they don't obey. More

And Finally... A London judge said UBS had the right to fire an analyst who chatted with a hedge fund friend about rumors relating to a Sanofi ($SNY) drug. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.